Literature DB >> 7793132

Influenza immunization policies in Europe and the United States.

K G Nicholson1, R Snacken, A M Palache.   

Abstract

Influenza vaccination policies of 28 European countries were compared with those of the US Immunization Practices Advisory Committee. Twenty-four of 28 (86%) European countries had immunization policies for influenza. European and US recommendations were in complete agreement concerning immunization of those with heart and lung disease. Within Europe there was 81-86% agreement concerning immunization of the elderly, irrespective of their health status, and patients with diabetes, renal dysfunction and immunosuppression, and 71% agreement concerning those in residential care and occupational groups that can transmit influenza to high-risk patients. Unlike the US, 62-71% of European countries did not target those with haemoglobinopathies, children and teenagers taking salicylates or household members of those at high risk. Few recommendations were endorsed by relevant medical or patient organizations. The observed variation in vaccination policies in Europe and North America possibly reflect uncertainties concerning risks from influenza and benefits from vaccination, and differences in public health systems and attitudes towards preventive medicine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793132     DOI: 10.1016/0264-410x(95)98258-c

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  Routine influenza vaccination for healthy children--old concept, new technologies.

Authors:  W E Beyer
Journal:  Arch Dis Child       Date:  2000-12       Impact factor: 3.791

2.  Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease?

Authors:  L J Tata; J West; T Harrison; P Farrington; C Smith; R Hubbard
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

3.  Economic evaluation of influenza vaccination and economic modelling.

Authors:  M Malek
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 4.  Evaluating the impact of influenza vaccination. A North American perspective.

Authors:  D S Fedson
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

Review 5.  Influenza vaccines. A reappraisal of their use.

Authors:  A M Palache
Journal:  Drugs       Date:  1997-12       Impact factor: 9.546

6.  Exercise prescription in primary care.

Authors:  F Smith; S Iliffe
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

7.  Influenza vaccine and older people: an evidence-based policy?

Authors:  M D Bradley; T A Sheldon; I S Watt
Journal:  Br J Gen Pract       Date:  1997-05       Impact factor: 5.386

Review 8.  Does influenza immunisation cause exacerbations of chronic airflow obstruction or asthma?

Authors:  J M Watson; J F Cordier; K G Nicholson
Journal:  Thorax       Date:  1997-02       Impact factor: 9.139

9.  Comparison of immunogenicity and safety of a virosome influenza vaccine with those of a subunit influenza vaccine in pediatric patients with cystic fibrosis.

Authors:  U B Schaad; U Bühlmann; R Burger; A Ruedeberg; A Wilder-Smith; M Rutishauser; F Sennhauser; C Herzog; M Zellmeyer; R Glück
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

10.  The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65 to 74 years.

Authors:  K L Nichol; M Goodman
Journal:  Pharmacoeconomics       Date:  1999       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.